INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP
NCT ID: NCT03547297
Last Updated: 2019-01-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
212 participants
OBSERVATIONAL
2018-05-29
2019-01-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence of Acute Hepatic Porphyria
NCT04923516
EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)
NCT02240784
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
NCT04883905
Pentoxifylline for Acute Alcoholic Hepatitis (AAH)
NCT00205049
Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C
NCT00252642
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Recurrent and severe episodes of abdominal pain that last for at least 24 hours
* At least 1 episode of severe abdominal pain that required an urgent healthcare visit in the past 12 months
* Other symptoms related to AHP that your doctor will discuss with you
* Willing and able to comply with protocol required assessments and provide written informed consent
Exclusion Criteria
* Alternative explanation for abdominal pain with clinical response to treatment specific for alternative diagnosis
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alnylam Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Quinn Dinh, MD
Role: STUDY_DIRECTOR
Alnylam Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trial Site
Pasadena, California, United States
Clinical Trial Site
Jacksonville, Florida, United States
Clinical Trial Site
Margate, Florida, United States
Clinical Trial Site
Ames, Iowa, United States
Clinical Trial Site
Las Vegas, Nevada, United States
Clinical Trial Site
Manhasset, New York, United States
Clinical Trial Site
Winston-Salem, North Carolina, United States
Clinical Trial Site
Pittsburgh, Pennsylvania, United States
Clinical Trial Site
Pottsville, Pennsylvania, United States
Clinical Trial Site
Knoxville, Tennessee, United States
Clinical Trial Site
Houston, Texas, United States
Clinical Trial Site
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALN-AS1-NT-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.